Common Contracts
2 similar null contracts by AEON Biopharma, Inc.
AEON BIOPHARMA, INC. AMENDMENT TO SUBORDINATED CONVERTIBLE PROMISSORY NOTEAEON Biopharma, Inc. • October 4th, 2021 • Pharmaceutical preparations
This Amendment (this “Amendment”) to the Subordinated Convertible Promissory Note, as defined below, is made as of May 10, 2021 (the “Effective Date”), by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceutical Co., Ltd., a company organized and existing under the laws of the Republic of Korea (the “Holder”). Capitalized terms used but not otherwise defined herein shall have the same meanings as set forth in the Note Purchase Agreement, as defined below, or the Original Note, as applicable.
AEON BIOPHARMA, INC. AMENDMENT TO SUBORDINATED CONVERTIBLE PROMISSORY NOTEAEON Biopharma, Inc. • October 4th, 2021 • Pharmaceutical preparations
This Amendment (this “Amendment”) to the Subordinated Convertible Promissory Note, as defined below, is made as of (the “Effective Date”), by and between AEON Biopharma, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceutical Co., Ltd., a company organized and existing under the laws of the Republic of Korea (the “Holder”). Capitalized terms used but not otherwise defined herein shall have the same meanings as set forth in the Note Purchase Agreement, as defined below, or the Original Note, as applicable.
